Injectable Generic Drugs: Prospects & Opportunities to 2010 (Revised Edition)
Injectable Generic Drugs: Prospects & Opportunities to 2010 (Revised Edition)
Published Date: October 2006
Published By: Espicom Healthcare Intelligence
Page Count: 228
Order Code: R16-76
Price: $2655 Online Download
$2665 Hard Copy Mail Delivery
This report will provide industry planners, commercial developers and the investment community with a thorough review of the operating landscape for generic injectables. The report is packed with primary source information and market forecasts, and takes a balanced view of the players and products that will shape this high value market sector.
A number of high value drugs due to come off patent in the USA and Europe over the next few years are injectable.
These include drugs to treat cancer, venous thrombosis, gastrointestinal disorders and hospital acquired infections. Alongside these and falling in the same therapeutic categories are drugs that have come off patent in the USA since 2004 and have attracted generic competition, such as cancer therapies carboplatin and paclitaxel.
Generic companies are also beginning to take an interest in some of the older high value biopharmaceuticals, including erythropoietin, filgrastim, recombinant insulin, somatropin and interferon. If regulatory hurdles can be overcome, the potential rewards for generic companies in biosimilar products are huge. This sector is still very new; to date, only two companies have successfully followed the regulatory path in Europe and it is proving even more difficult to attain regulatory approval for biosimilars in the US.
The traditional view of generic drugs is that they offer a cheap alternative to their branded equivalents. Cost has been an important factor in their development, particularly for oral drugs that are relatively cheap to produce and can be introduced to that market at a fraction of the price of the original drug. Generic companies are, however, beginning to look for higher profit margins and injectable drugs potentially offer such opportunities.
Combined branded and generic sales of the non-biological injectables included in this study were around US$20.5 billion in 2005, of which around US$12.0 billion will lose patent protection in the US by 2010. The proprietary biopharmaceuticals that we believe are most likely to become available as generics once the legal hurdles to registration have been overcome, currently have combined sales in the region of US$27.2 billion.
